A2 Biotherapeutics, Inc. | $80,000,000 | (Jan 10, 2025)
Prudentia Sciences | $7,000,000 | (Jan 10, 2025)
RLTYco | $20,000,000 | (Jan 10, 2025)
Certified by Founder
Lodge
Oxford Cancer Analytics
start up
United Kingdom
- Oxford, England
- 10/01/2025
- Series A
- $11,000,000
Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.
- Industry Biotechnology
- Website https://www.oxcan.org/
- LinkedIn https://www.linkedin.com/company/oxford-cancer-analytics/
Air | $35,000,000 | (Jan 10, 2025)
Biosphere | $8,800,000 | (Jan 10, 2025)
RyboDyn Inc. | $4,000,000 | (Jan 10, 2025)
Abstract(US) | $4,800,000 | (Jan 10, 2025)
PrettyDamnQuick | $25,000,000 | (Jan 10, 2025)
UNLISTED | $2,250,000 | (Jan 9, 2025)
Zeto / Rapid Full-Montage EEG | $31,000,000 | (Jan 9, 2025)
Red Rover Health, Inc. | $4,000,000 | (Jan 9, 2025)